Vimarsana
Biggest News Aggregation in the World

Page 2 - History Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from History Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In History Study Today - Breaking & Trending Today

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndr - Vimarsana News

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndr

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Analysis of 72 patients treated in STK-001 clinical trials suggests that higher...

Sohonos Approved for Fibrodysplasia Ossificans Progressiva - Vimarsana News

Sohonos Approved for Fibrodysplasia Ossificans Progressiva

The FDA has approved Sohonos™ (palovarotene) for patients with fibrodysplasia ossificans progressiva.

Source: empr.com
Myelodysplastic syndromes are commonly misdiagnosed, study finds - Vimarsana News

Myelodysplastic syndromes are commonly misdiagnosed, study finds

Blood disorders known as myelodysplastic syndromes/neoplasms (MDS) are difficult to diagnose – and are commonly misdiagnosed – putting patients at increased risk for treatment mistakes and other potentially harmful consequences, according to researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations.

MDS Diagnoses Need an Expert Opinion - Vimarsana News

MDS Diagnoses Need an Expert Opinion

Patients with myelodysplastic syndrome should seek an expert opinion on their disease to ensure an accurate diagnosis and proper treatment plan.

Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study - Vimarsana News

Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF...